miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer
出版年份 2014 全文链接
标题
miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer
作者
关键词
MicroRNA-630, IGF1R, Biomarker, Breast cancer, Drug resistance, Cancer cell aggression
出版物
Molecular Cancer
Volume 13, Issue 1, Pages 71
出版商
Springer Nature
发表日期
2014-03-24
DOI
10.1186/1476-4598-13-71
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma
- (2013) Sweta Rani et al. CANCER BIOLOGY & THERAPY
- Angiopoietin-like protein 1 suppresses SLUG to inhibit cancer cell motility
- (2013) Tsang-Chih Kuo et al. JOURNAL OF CLINICAL INVESTIGATION
- Upregulation of miR-150* and miR-630 Induces Apoptosis in Pancreatic Cancer Cells by Targeting IGF-1R
- (2013) Lulu Farhana et al. PLoS One
- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
- (2012) Nancy U. Lin et al. BREAST CANCER RESEARCH AND TREATMENT
- Increased signalling of EGFR and IGF1R and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
- (2012) A Gallardo et al. BRITISH JOURNAL OF CANCER
- miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours
- (2012) Francesca Biagioni et al. EMBO Molecular Medicine
- Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines
- (2012) Fiona O’Neill et al. Molecular Cancer
- Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes
- (2012) Claire Corcoran et al. PLoS One
- PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
- (2011) Leiping Wang et al. BMC CANCER
- IGF1R-Targeted Therapy and Its Enhancement of Doxorubicin Chemosensitivity in Human Osteosarcoma Cell Lines
- (2011) Frederick Luk et al. CANCER INVESTIGATION
- Phospho-ΔNp63α is a key regulator of the cisplatin-induced microRNAome in cancer cells
- (2011) Y Huang et al. CELL DEATH AND DIFFERENTIATION
- Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells
- (2010) B. C. Browne et al. ANNALS OF ONCOLOGY
- Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer
- (2010) Anne M. Friel et al. BREAST CANCER RESEARCH AND TREATMENT
- miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death
- (2010) L. Galluzzi et al. CANCER RESEARCH
- Intracellular and Extracellular MicroRNAs in Breast Cancer
- (2010) C. Corcoran et al. CLINICAL CHEMISTRY
- Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo
- (2010) Yin-He Wang et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
- (2010) N. A. O'Brien et al. MOLECULAR CANCER THERAPEUTICS
- Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
- (2009) L. Liu et al. CANCER RESEARCH
- HER-2 Signaling and Inhibition in Breast Cancer
- (2009) B. Browne et al. CURRENT CANCER DRUG TARGETS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started